Surface Logix, Inc. to Present at the Piper Jaffray Health Care Conference
Surface Logix currently has two programs in human clinical trials with athird program in the IND preparation stage. Mr. Mahoney will discuss thelatest results for SLx-2101 and SLx-4090. SLx-2101, a second-generation PDE5inhibitor designed to address cardiovascular indications, is currently in twoseparate Phase 2a trials, one in hypertension and another in Raynaud'ssyndrome. SLx-4090, a first-in-class enterocyte-specific MTP inhibitor for thetreatment of dyslipidemia and potentially other indications, is also in Phase2a.
About Surface Logix, Inc.
Surface Logix, Inc. uses its expertise in biophysical chemistry to createand develop novel small molecule drugs (NCEs) with superior drug-likeproperties that are clearly differentiated from competitive products. Thecompany is advancing multiple internal programs focused primarily oncardiovascular, metabolic, oncologic and fibrotic diseases. For moreinformation, please visit http://www.surfacelogix.com.Contact: Leland Webster, Ph.D., M.B.A. Surface Logix Inc. Vice President, Corporate Development 617.746.8520 Media: Sarah Cavanaugh MacDougall Biomedical Communications, Inc. email@example.com 508.647.0209
SOURCE Surface Logix, Inc.
You May Also Like